Abstract:
Sepsis is a clinical syndrome characterized by a multisystem response to a pathogenic assault due to underlying infection involves conglomerate of interconnected biochemical, cellular, and organ-organ interaction networks. After withdrawal of recombinant human activated protein C (rAPC), researchers and physicians have been striving in search of new therapeutic approaches and targets against sepsis, effective in both hypo and hyper inflammatory states. Currently statins are being evaluated as a viable option in clinical trials. Many agents which have shown favorable results in experimental sepsis are not clinically effective or have not been clinically evaluated. Apart from developing new therapeutic molecules there is a huge scope of employing various drug delivery strategies like nanoparticulate carriers and phospholipid based systems. These nanoparticulate carriers neutralize intracorporeal LPS as well as target various therapeutic agents to tissues and sub-cellular locations. This perspective manuscript reviews and critically discusses recent status, experimental and clinical approaches for therapeutic intervention of sepsis.
